Moreover, in the Dapa-heart failure trials in the patients with heart failure with decreased ejection fraction (HFrEF), the SGLT2 inhibitor (e.g., Dapa) presents an obvious cardiovascular benefit, regardless of patients with/without T2D [10]. Here, SLC5A2 is linked to type 2 diabetes mellitus.